(+)-JQ1

Catalog No.S7110

Molecular Weight(MW): 456.99

(+)-JQ1 is a BET bromodomain inhibitor, with IC50 of 77 nM/33 nM for BRD4(1/2) in cell-free assays, binding to all bromodomains of the BET family, but not to bromodomains outside the BET family.

Cited by 198 Publications

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Cancer Cell, 2018, 34(2):271-285.e7

PubMed: 30107177 ( click the link to review the publication )

Cancer Cell, 2018, 33(3):401-416

PubMed: 29533782 ( click the link to review the publication )

Nat Med, 2017, 23(4):493-500

PubMed: 28263307 ( click the link to review the publication )

Nat Med, 2017, 23(9):1046-1054

PubMed: 28805821 ( click the link to review the publication )

Cancer Discov, 2017, 7(3):302-321

PubMed: 28108460 ( click the link to review the publication )

Cancer Cell, 2017, 31(5):635-652

PubMed: 28434841 ( click the link to review the publication )

Gastroenterology, 2014, 147(5):1119-33

PubMed: 25127677 ( click the link to review the publication )

Nat Commun, 2020, 11(1):71

PubMed: 31900415 ( click the link to review the publication )

Sci Transl Med, 2019, 11(497)

PubMed: 31217338 ( click the link to review the publication )

Blood, 2019, 134(21):1821-1831

PubMed: 31527074 ( click the link to review the publication )

Nat Commun, 2019, 10(1):335

PubMed: 30659195 ( click the link to review the publication )

Nat Commun, 2019, 10(1):3201

PubMed: 31324758 ( click the link to review the publication )

EMBO Mol Med, 2019, 11(2)

PubMed: 30610113 ( click the link to review the publication )

EMBO Mol Med, 2019, 11(10):e9930

PubMed: 31476112 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2019, 116(6):2220-2225

PubMed: 30659143 ( click the link to review the publication )

Cancer Res, 2019, 79(9):2415-2425

PubMed: 30885979 ( click the link to review the publication )

Cell Syst, 2019, 8(2):97-108

PubMed: 30797775 ( click the link to review the publication )

J Immunother Cancer, 2019, 7(1):277

PubMed: 31653272 ( click the link to review the publication )

Theranostics, 2019, 9(13):3840-3852

PubMed: 31281517 ( click the link to review the publication )

Cancer Res, 2019, 79(19):4869-4881

PubMed: 31311807 ( click the link to review the publication )

Cancer Res, 2019, 79(18):4599-4611

PubMed: 31358529 ( click the link to review the publication )

Cell Rep, 2019, 28(13):3497-3509

PubMed: 31553917 ( click the link to review the publication )

Cell Rep, 2019, 27(11):3331-3344

PubMed: 31189115 ( click the link to review the publication )
Elife, 2019, 8

PubMed: 30652970 ( click the link to review the publication )

J Hematol Oncol, 2019, 12(1):73

PubMed: 31288832 ( click the link to review the publication )

Redox Biol, 2019, 24:101195

PubMed: 31004990 ( click the link to review the publication )

Oncogene, 2019, 38(47):7249-7265

PubMed: 31420604 ( click the link to review the publication )

Cancer Lett, 2019, 442:373-382

PubMed: 30419347 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):383

PubMed: 31470872 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):83

PubMed: 30770740 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):463

PubMed: 31718704 ( click the link to review the publication )

Cell Death Dis, 2019, 10(8):557

PubMed: 31324754 ( click the link to review the publication )

Cell Death Dis, 2019, 10(4):324

PubMed: 30975979 ( click the link to review the publication )

Cell Death Dis, 2019, 10(11):815

PubMed: 31653826 ( click the link to review the publication )

Addict Biol, 2019, 10.1111/adb.12808

PubMed: 31364211 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(11):2111-2123

PubMed: 31467179 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(5):900-908

PubMed: 30824609 ( click the link to review the publication )

Epigenetics, 2019, 10.1080/15592294.2019.1656156

PubMed: 31423932 ( click the link to review the publication )

J Thorac Cardiovasc Surg, 2019, 10.1016/j.jtcvs.2019.06.115

PubMed: 31564537 ( click the link to review the publication )

Sci Rep, 2019, 9(1):13305

PubMed: 31527644 ( click the link to review the publication )

Sci Rep, 2019, 9(1):17369

PubMed: 31758083 ( click the link to review the publication )

Biomed Pharmacother, 2019, 114:108793

PubMed: 30921702 ( click the link to review the publication )

BMC Cancer, 2019, 19(1):1251

PubMed: 31881855 ( click the link to review the publication )

Biochem Biophys Res Commun, 2019, 519(3):481-488

PubMed: 31530390 ( click the link to review the publication )

J Oral Pathol Med, 2019, 10.1111/jop.12906

PubMed: 31177574 ( click the link to review the publication )

SLAS Discov, 2019, 24(2):142-157

PubMed: 30204533 ( click the link to review the publication )

Mol Med Rep, 2019, 19(1):499-507

PubMed: 30483785 ( click the link to review the publication )
Oncol Lett, 2019, 18(3):2340-2347

PubMed: 31452730 ( click the link to review the publication )

Journal of Oral Pathology & Medicine, 2019, 10.1111/jop.12906

PubMed: 无 ( click the link to review the publication )

Mol Cell, 2018, 72(2):341-354

PubMed: 30270106 ( click the link to review the publication )

J Clin Invest, 2018, 128(1):387-401

PubMed: 29200404 ( click the link to review the publication )

Nat Commun, 2018, 9(1):1532

PubMed: 29670088 ( click the link to review the publication )

Nat Commun, 2018, 9(1):3815

PubMed: 30232459 ( click the link to review the publication )

EMBO J, 2018, 37(5)

PubMed: 29440228 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2018, 115(40):E9317-E9324

PubMed: 30181285 ( click the link to review the publication )

J Am Soc Nephrol, 2018, 29(6):1690-1705

PubMed: 29739813 ( click the link to review the publication )

Cancer Res, 2018, 78(10):2705-2720

PubMed: 29490948 ( click the link to review the publication )

Cell Rep, 2018, 22(8):2016-2025

PubMed: 29466730 ( click the link to review the publication )

Cell Rep, 2018, 24(7):1722-1729

PubMed: 30110629 ( click the link to review the publication )

Oncogene, 2018, 37(28):3763-3777

PubMed: 29636547 ( click the link to review the publication )

J Med Chem, 2018, 61(2):453-461

PubMed: 28378579 ( click the link to review the publication )

Cancers (Basel), 2018, 10(1)

PubMed: 29346274 ( click the link to review the publication )

Clin Epigenetics, 2018, 10:01

PubMed: 29312470 ( click the link to review the publication )

Cells, 2018, 7(10)

PubMed: 30304769 ( click the link to review the publication )

Exp Mol Med, 2018, 50(1):e419

PubMed: 29303513 ( click the link to review the publication )

Cell Physiol Biochem, 2018, 50(2):798-809

PubMed: 30308485 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(12):2796-2810

PubMed: 30242092 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(7):1554-1565

PubMed: 29716963 ( click the link to review the publication )

Gynecol Oncol, 2018, 149(3):575-584

PubMed: 29567272 ( click the link to review the publication )

J Virol, 2018, 92(10)

PubMed: 29343578 ( click the link to review the publication )

J Virol, 2018, 92(2)

PubMed: 29118124 ( click the link to review the publication )
Epigenetics Chromatin, 2018, 11(1):30

PubMed: 29884215 ( click the link to review the publication )

Sci Rep, 2018, 8(1):3521

PubMed: 29476067 ( click the link to review the publication )

Sci Rep, 2018, 8(1):998

PubMed: 29343723 ( click the link to review the publication )

Sci Rep, 2018, 8(1):18043

PubMed: 30575780 ( click the link to review the publication )

Front Microbiol, 2018, 9:2022

PubMed: 30283406 ( click the link to review the publication )

J Biol Chem, 2018, 293(16):5808-5820

PubMed: 29475942 ( click the link to review the publication )

Int J Oncol, 2018, 53(6):2503-2517

PubMed: 30272279 ( click the link to review the publication )

Retrovirology, 2018, 15(1):36

PubMed: 29751762 ( click the link to review the publication )

Invest Ophthalmol Vis Sci, 2018, 59(1):132-143

PubMed: 29332125 ( click the link to review the publication )

Bioorg Med Chem, 2018, 26(1):25-36

PubMed: 29170024 ( click the link to review the publication )

Int J Stem Cells, 2018, 11(1):131-140

PubMed: 29699387 ( click the link to review the publication )

Biochem Biophys Res Commun, 2018, 499(3):531-537

PubMed: 29596834 ( click the link to review the publication )

Leuk Lymphoma, 2018, 59(4):931-940

PubMed: 28750570 ( click the link to review the publication )

Leuk Lymphoma, 2018, 59(5):1248-1251

PubMed: 28885069 ( click the link to review the publication )

Oncotarget, 2018, 9(71):33482-33499

PubMed: 30323893 ( click the link to review the publication )

Blood Adv, 2018, 2(23):3428-3442

PubMed: 30504235 ( click the link to review the publication )

Oncotarget, 2018, 9(11):9907-9924

PubMed: 29515779 ( click the link to review the publication )

Oncotarget, 2018, 9(41):26491-26506

PubMed: 29899872 ( click the link to review the publication )

Oncotarget, 2018, 9(83):35408-35421

PubMed: 30459933 ( click the link to review the publication )

JCI Insight, 2018, 3(19)

PubMed: 30282829 ( click the link to review the publication )

JCI Insight, 2018, 3(16)

PubMed: 30135308 ( click the link to review the publication )

Cell Host Microbe, 2017, 21(5):569-579

PubMed: 28494238 ( click the link to review the publication )

Nat Chem Biol, 2017, 13(6):681-690

PubMed: 28437395 ( click the link to review the publication )

Nat Commun, 2017, 8:16078

PubMed: 28714472 ( click the link to review the publication )
Nat Commun, 2017, 8:16078

PubMed: 28714472 ( click the link to review the publication )

Nat Commun, 2017, 8:14802

PubMed: 28378740 ( click the link to review the publication )

Nat Commun, 2017, 8(1):1067

PubMed: 29057925 ( click the link to review the publication )

Nucleic Acids Res, 2017, 45(14):8403-8410

PubMed: 28854735 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(15):4462-4472

PubMed: 28270499 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2017, 114(36):E7554-E7563

PubMed: 28784769 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2017, 114(27):E5352-E5361

PubMed: 28630312 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2017, 114(43):E9135-E9144

PubMed: 29073110 ( click the link to review the publication )

Genes Dev, 2017, 31(12):1212-1227

PubMed: 28724615 ( click the link to review the publication )

Cancer Res, 2017, 77(20):5564-5575

PubMed: 28819026 ( click the link to review the publication )

J Am Soc Nephrol, 2017, 28(2):504-519

PubMed: 27436852 ( click the link to review the publication )

Mol Syst Biol, 2017, 13(1):905

PubMed: 28069687 ( click the link to review the publication )

Cell Rep, 2017, 21(10):2796-2812

PubMed: 29212027 ( click the link to review the publication )

Haematologica, 2017, 102(10):1776-1784

PubMed: 28751557 ( click the link to review the publication )

Cell Mol Immunol, 2017, 14(4):371-379

PubMed: 26388239 ( click the link to review the publication )

Sci Signal, 2017, 10(508)

PubMed: 29208683 ( click the link to review the publication )

J Med Chem, 2017, 60(24):9990-10012

PubMed: 29172540 ( click the link to review the publication )

J Med Chem, 2017, 60(14):6289-6304

PubMed: 28650658 ( click the link to review the publication )

Cancer Discov, 2017, 7(12):1436-1449

PubMed: 28923910 ( click the link to review the publication )

Cancer Discov, 2017, 7(8):852-867

PubMed: 28408401 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(2):285-299

PubMed: 27980108 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(9):1739-1750

PubMed: 28572168 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(6):1054-1067

PubMed: 28336808 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(6):1155-1165

PubMed: 28246302 ( click the link to review the publication )
Biochim Biophys Acta Mol Basis Dis, 2017, 1863(12):3001-3015

PubMed: 28844955 ( click the link to review the publication )

Mol Cancer Res, 2017, 15(1):35-44

PubMed: 27707886 ( click the link to review the publication )

Mol Cancer Res, 2017, 15(8):984-997

PubMed: 28442587 ( click the link to review the publication )

Sci Rep, 2017, 7(1):8027

PubMed: 28808321 ( click the link to review the publication )

Skelet Muscle, 2017, 7(1):16

PubMed: 28870238 ( click the link to review the publication )

J Chem Inf Model, 2017, 57(7):1677-1690

PubMed: 28636361 ( click the link to review the publication )

Org Biomol Chem, 2017, 15(44):9352-9361

PubMed: 29087414 ( click the link to review the publication )

Biomed Pharmacother, 2017, 95:1574-1579

PubMed: 28950657 ( click the link to review the publication )

J Agric Food Chem, 2017, 65(22):4384-4394

PubMed: 28471170 ( click the link to review the publication )

Cell Biosci, 2017, 7:56

PubMed: 29118968 ( click the link to review the publication )

Molecules, 2017, 23(1)

PubMed: 29295560 ( click the link to review the publication )

Onco Targets Ther, 2017, 10:2581-2593

PubMed: 28553123 ( click the link to review the publication )

J Gen Virol, 2017, 98(4):799-809

PubMed: 28113052 ( click the link to review the publication )

Biol Res, 2017, 50(1):19

PubMed: 28545522 ( click the link to review the publication )

Oncotarget, 2017, 8(18):29558-29573

PubMed: 28418907 ( click the link to review the publication )

Oncotarget, 2017, 8(23):37140-37153

PubMed: 28415755 ( click the link to review the publication )

Oncotarget, 2017, 9(9):8334-8349

PubMed: 29492199 ( click the link to review the publication )

Oncotarget, 2017, 8(63):107206-107222

PubMed: 29291023 ( click the link to review the publication )

Oncotarget, 2017, 8(58):98068-98083

PubMed: 29228674 ( click the link to review the publication )

Oncotarget, 2017, 8(49):86312-86324

PubMed: 29156797 ( click the link to review the publication )

Oncotarget, 2017, 8(31):51402-51415

PubMed: 28881656 ( click the link to review the publication )

Oncotarget, 2017, 8(58):98471-98481

PubMed: 29228703 ( click the link to review the publication )

Sci Rep, 2017, 7(1):16646

PubMed: 29192216 ( click the link to review the publication )

Nat Chem Biol, 2016, 12(7):504-10

PubMed: 27159579 ( click the link to review the publication )
EMBO Mol Med, 2016, 8(2):117-38

PubMed: 26681773 ( click the link to review the publication )

Clin Cancer Res, 2016, 10.1158/1078-0432.CCR-15-2448

PubMed: 27401245 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2016, 113(42):11865-11870

PubMed: 27679845 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2016, 113(31):E4558-66

PubMed: 27432991 ( click the link to review the publication )

Cancer Res, 2016, 76(11):3319-31

PubMed: 26988986 ( click the link to review the publication )

Clin Cancer Res, 2016, 22(17):4440-51

PubMed: 27103402 ( click the link to review the publication )

Cancer Res, 2016, 76(5):1204-13

PubMed: 26837760 ( click the link to review the publication )

Cancer Res, 2016, 76(8):2376-83

PubMed: 26941288 ( click the link to review the publication )

Cancer Res, 2016, 76(6):1313-9

PubMed: 26759243 ( click the link to review the publication )

Cell Rep, 2016, 16(5):1366-1378

PubMed: 27425608 ( click the link to review the publication )

Cell Rep, 2016, 15(2):310-22

PubMed: 27050521 ( click the link to review the publication )

J Hematol Oncol, 2016, 9(1):134

PubMed: 27903272 ( click the link to review the publication )

PLoS Pathog, 2016, 12(10):e1005950

PubMed: 27764245 ( click the link to review the publication )

Clin Epigenetics, 2016, 8:76

PubMed: 27437033 ( click the link to review the publication )

PLoS Genet, 2016, 12(9):e1006279

PubMed: 27588951 ( click the link to review the publication )

Cancer Discov, 2016, 6(6):612-29

PubMed: 27099234 ( click the link to review the publication )

Mol Cancer Ther, 2016, 10.1158/1535-7163.MCT-15-0750

PubMed: 26939702 ( click the link to review the publication )

Mol Cancer Ther, 2016, 15(6):1217-26

PubMed: 26983878 ( click the link to review the publication )

J Virol, 2016, 90(18):8059-73

PubMed: 27356901 ( click the link to review the publication )

J Biol Chem, 2016, 291(41):21694-21702

PubMed: 27576686 ( click the link to review the publication )

Oncol Rep, 2016, 36(4):1989-96

PubMed: 27573714 ( click the link to review the publication )

Biochem Biophys Res Commun, 2016, 469(3):679-85

PubMed: 26707881 ( click the link to review the publication )

Oncotarget, 2016, 6(7):5134-46

PubMed: 25762617 ( click the link to review the publication )

Oncotarget, 2016, 7(6):6576-92

PubMed: 26536665 ( click the link to review the publication )
Sci Rep, 2016, 6:23770

PubMed: 27044328 ( click the link to review the publication )

Oncotarget, 2016, 8(32):52193-52210

PubMed: 28881723 ( click the link to review the publication )

Blood, 2015, 126(13):1565-74

PubMed: 26254443 ( click the link to review the publication )

Nat Commun, 2015, 6:10091

PubMed: 26631872 ( click the link to review the publication )

Sci Adv, 2015, 1(8):e1500221

PubMed: 26601252 ( click the link to review the publication )

Cancer Res, 2015, 75(21):4548-59

PubMed: 26483207 ( click the link to review the publication )

J Hematol Oncol, 2015, 8:121

PubMed: 26515759 ( click the link to review the publication )

EBioMedicine, 2015, 3:108-121

PubMed: 26870822 ( click the link to review the publication )

Arch Toxicol, 2015, 89(2):179-91

PubMed: 25559776 ( click the link to review the publication )

Epigenetics, 2015, 10.1080/15592294.2015.1034416

PubMed: 25941994 ( click the link to review the publication )

Sci Rep, 2015, 5:16445

PubMed: 26563568 ( click the link to review the publication )

Sci Rep, 2015, 5:10120

PubMed: 25944566 ( click the link to review the publication )

Cancer Biol Ther, 2015, 16(4):580-8

PubMed: 25793663 ( click the link to review the publication )

Exp Ther Med, 2015, 10(6):2319-2324

PubMed: 26668635 ( click the link to review the publication )

Oncotarget, 2015, 6(22):18921-32

PubMed: 26254279 ( click the link to review the publication )

Oncotarget, 2015, 6(11):8722-35

PubMed: 25749378 ( click the link to review the publication )

Oncotarget, 2015, 6(32):33623-35

PubMed: 26378038 ( click the link to review the publication )

Oncotarget, 2015, 6(25):21507-21

PubMed: 26087189 ( click the link to review the publication )

Nat Chem Biol, 2014, 10(4):305-12

PubMed: 24584101 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2014, 111(26):E2721-30

PubMed: 24979794 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2014, 111(26):9503-8

PubMed: 24979803 ( click the link to review the publication )

Cancer Res, 2014, 74(23):7090-102

PubMed: 25277525 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(11):2898-909

PubMed: 24714777 ( click the link to review the publication )

Cancer Res, 2014, 74(21):5999-6009

PubMed: 25164011 ( click the link to review the publication )
Mol Cell Proteomics, 2014, 13(11):2896-910

PubMed: 25106422 ( click the link to review the publication )

Epigenetics, 2014, 9(4):611-20

PubMed: 24496381 ( click the link to review the publication )

Drug Metab Dispos, 2013, 41(10):1725-31

PubMed: 23918665 ( click the link to review the publication )

PLoS One, 2013, 8(5):e63563

PubMed: 23704919 ( click the link to review the publication )

Nat Chem Biol, 2012, 8(11):905-912

PubMed: 23023260 ( click the link to review the publication )

Handb Exp Pharmacol, 2011, 206:1-12

PubMed: 21879443 ( click the link to review the publication )

Purity & Quality Control

Choose Selective Epigenetic Reader Domain Inhibitors

Biological Activity

Description

Features

(+)-JQ1 is more effective than (-)-JQ1.

Targets

BRD4 (2) ^[1] (Cell-free assay)	BRD4 (1) ^[1] (Cell-free assay)
33 nM	77 nM

In vitro

(+)-JQ1 enantiomer binds directly into the Kac binding site of BET bromodomains. (+)-JQ1 (500 nM) binds BRD4 competitively with chromatin resulting in differentiation and growth arrest of NMC cells. (+)-JQ1 (500 nM) attenuates rapid proliferation of NMC 797 and Per403 cell lines as demonstrated by reduced Ki67 staining. (+)-JQ1 (500 nM) potently decreases expression of both BRD4 target genes in NMC 797 cells. (+)-JQ1 inhibits cellular viability with IC50 of 4 nM in NMC 11060 cells. ^[1] (+)-JQ1 results in robust inhibition of MYC expression in MM cell lines. (+)-JQ1 inhibits proliferating of KMS-34 and LR5 with IC50 of 68 nM and 98 nM, respectively. (+)-JQ1 (500 nM)-treated MM.1S cells results in a pronounced decrease in the proportion of cells in S-phase, with a concomitant increase in cells arrested in G0/G1. (+)-JQ1 (500 nM) results in pronounced cellular senescence by beta-galactosidase staining. (+)-JQ1 (800 nM) exposure leads to a significant reduction in cell viability among the majority of CD138+ patient-derived MM samples tested. ^[2] (+)-JQ1 inhibits growth of LP-1 cells with GI50 of 98 nM. (+)-JQ1 (625 nM) results in an increase in the percentage of LP-1 cells in G0/G1. (+)-JQ1 (500 nM) suppresses the expression of MYC, BRD4 and CDK9 in LP-1 cells. ^[3] (+)-JQ1 (1 μM) activates HIV transcription in latently infected Jurkat T cells. (+)-JQ1 (50 μM) stimulates predominantly Tat-dependent HIV transcription in both Jurkat and HeLa cells. (+)-JQ1 (5 μM) induces Brd4 dissociation enables Tat to recruit SEC to HIV promoter and induce Pol II CTD phosphorylation and viral transcription in J-Lat A2 cells. JQ1 enables Tat to increase CDK9 T-loop phosphorylation and partially dissociates P-TEFb from 7SK snRNP in Jurkat T cells. ^[4]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
K1	M{jGbWNmdGxiVnnhZoltcXS7IFHzd4F6	M1q5dFI2OC93MECvNVAxOCCwTR?=	MlX4NlQwPDhxN{KgbC=>	NHf6fYNFVVOR	MnLybY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliaX6gZo91cCCmb4PlMUBidmRidHnt[U0h\GWyZX7k[Y51KG2jbn7ldi=>	MUOyOlcxPzh6MR?=
BCPAP	MmPiR4VtdCCYaXHibYxqfHliQYPzZZk>	M1TaTlI2OC93MECvNVAxOCCwTR?=	NEDNdGQzPC92OD:3NkBp	NXjhUJFVTE2VTx?=	M4Xx[4lvcGmkaYTzJINmdGxidnnhZoltcXS7IHnuJIJwfGhiZH;z[U0h[W6mIITpcYUuKGSncHXu[IVvfCCvYX7u[ZI>	NFj0RpozPjdyN{i4NS=>
K1	MYLD[YxtKEO7Y3zlJGF{e2G7	M3jrOFI2OC93MECvNVAxOCCwTR?=	M4nSZ\|czKGh?	M1ruWWROW09?	MmnpZZJz\XO2czDj[YxtKGO7Y3zlJIF1KEdyL1exJJBp[XOn	MYiyOlcxPzh6MR?=
BCPAP	NHrwOJBE\WyuIFP5Z4xmKEG\|c3H5	MlTCNlUxNzVyMD:xNFAxKG6P	NV3FU\|dTPzJiaB?=	MXjEUXNQ	NGD5NYpienKnc4TzJINmdGxiY4njcIUh[XRiR{CvS\|EheGijc3W=	NWXydXNpOjZ5MEe4PFE>
Hep3B	M4ixSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M130ZlAuOTBizszN	M1HZV\|Uh\A>?	M{LzWGROW09?	MXfJR\|UxRTBwMEig{txO	NWXKbZJZOjZ3N{WxOlc>
HCCLM3	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYXrNYFqOC1zMDFOwG0>	Mm\1OUBl	NGDC[pZFVVOR	NFLXWZVKSzVyPUCuNVQh\|ryP	MkPENlY2PzVzNke=
HuH7	NIHoeJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3\QN\|AuOTBizszN	M1vmVlUh\A>?	NEGzN2pFVVOR	MWXJR\|UxRTBwMkGg{txO	NWHLXok2OjZ3N{WxOlc>
HepG2	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUTXc\|NsOC1zMDFOwG0>	MnLMOUBl	NWjkR3NGTE2VTx?=	NGDqVYNKSzVyPUCuN\|Qh\|ryP	MoLkNlY2PzVzNke=
SMMC7721	MlfGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV2wMVExKM7:TR?=	NGjUNVA2KGR?	NIn2ZYlFVVOR	NXX4[mI{UUN3ME2wMlQyKM7:TR?=	Mmq4NlY2PzVzNke=
BEL7402	NF7uNmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYHxcZJDOC1zMDFOwG0>	MXq1JIQ>	M2L5UGROW09?	MVrJR\|UxRTBwNEeg{txO	M3PlUlI3PTd3MU[3
MHCC97H	M3zVbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MU[wMVExKM7:TR?=	NY\0fmgxPSCm	NGq1[o9FVVOR	M{PuRmlEPTB;MD60NUDPxE1?	MoPMNlY2PzVzNke=
Hep3B	MoHTR4VtdCCFeXPs[UBCe3OjeR?=	Mn3lNE4yNzBwNT:yMlUh\|ryP	NI\r[Zk1QCCq	MmXiSG1UVw>?	M33scoxm[WS\|IITvJIEhe3Wkc4ThcpRq[WxiYXPjeY12dGG2aX;uJI9nKEiFQzDj[YxteyCrbjDzeYIuTzFicHjhd4XDqA>?	M4\ROFI3PTd3MU[3
HCCLM3	MlPxR4VtdCCFeXPs[UBCe3OjeR?=	NH7Wb5YxNjFxMD61M\|IvPSEQvF2=	MUm0PEBp	NGD4cVFFVVOR	MljscIVi\HNidH:gZUB{fWK\|dHHueIlidCCjY3P1cZVt[XSrb36gc4YhUEOFIHPlcIx{KGmwIIP1Zk1IOSCyaHHz[eKh	NXHmXYZnOjZ3N{WxOlc>
Hep3B	NXzq[XN7SXCxcITvd4l{KEG\|c3H5	NUDmNGt7OC5zL{CuOU8zNjVizszN	MlnoOFghcA>?	MVvEUXNQ	M1vpc4FkfGm4YYTld{Bk[XOyYYPlMVMh[W6mIHPhd5Bie2VvOTDlfJBz\XO\|aX;uJIFv\CCrbnT1Z4VlKFCDUmCgZ4xm[X[jZ3WgZZMhf2WubDDhd{BkgXSxY3jyc41mKGNicnXs[YF{\SCrboTvJJRp\SCleYTvdIxie21iZoLvcUBucXSxY3jvcoRzcWF?	MX6yOlU4PTF4Nx?=
HCCLM3	M1jOXGFxd3C2b4Ppd{BCe3OjeR?=	MmS4NE4yNzBwNT:yMlUh\|ryP	M4rhSFQ5KGh?	M4Hac2ROW09?	M2PDfoFkfGm4YYTld{Bk[XOyYYPlMVMh[W6mIHPhd5Bie2VvOTDlfJBz\XO\|aX;uJIFv\CCrbnT1Z4VlKFCDUmCgZ4xm[X[jZ3WgZZMhf2WubDDhd{BkgXSxY3jyc41mKGNicnXs[YF{\SCrboTvJJRp\SCleYTvdIxie21iZoLvcUBucXSxY3jvcoRzcWF?	NUTUNI5zOjZ3N{WxOlc>
A549	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFT1[lcxNjFvMUCg{txO	NH[wZ4E4OiCq		M1KweYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz	NHnPcYMzPjRzNUKyOS=>
H157	M4DHbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYPT[GxmOC5zLUGwJO69VQ>?	M2PqVlczKGh?		M1qwR4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz	Mn3sNlY1OTV{MkW=
H1299	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2\EUFAvOS1zMDFOwG0>	MkHCO\|IhcA>?		NFHjXHBqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>?	NUnSUGczOjZ2MUWyNlU>
A549	MmjYSpVv[3Srb36gRZN{[Xl?	NW\DbJgyOS9{LkWvOUDPxE1?	NX;CVY1POTJiaB?=		NUDURY51yqC5ZXHrcJkh\GWlcnXhd4VlKEKlbD2yJIxmfmWucx?=	MXuyOlQyPTJ{NR?=
H1299	MonKSpVv[3Srb36gRZN{[Xl?	MnPKNU8zNjVxNTFOwG0>	NUHCboNHOTJiaB?=		M1fiWOKhf2Wja3z5JIRm[3KnYYPl[EBD[2xvMjDs[ZZmdHN?	M{i0PFI3PDF3MkK1
H157	MXjGeY5kfGmxbjDBd5NigQ>?	NEmycZEyNzJwNT:1JO69VQ>?	MWWxNkBp		NHW0[oxl\WO{ZXHz[YQhTFJ2IHX4dJJme3Orb36=	M1rLSVI3PDF3MkK1
H1299	NHTQWnFHfW6ldHnvckBCe3OjeR?=	M4nRUFEwOi53L{Wg{txO	NYSzVYY3OTJiaB?=		MoXu[IVkemWjc3XkJGRTPCCneIDy[ZN{cW:w	NFHBcIgzPjRzNUKyOS=>
C8161	MVrD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	M4LZSVAuOiEQvF2=	NVi4[VFVPCCm	MVvEUXNQ	NH7DW3Nl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK=	NXXoVVVMOjZ\|OUeyNlM>
Mel285	M2nXc2NmdGxiVnnhZoltcXS7IFHzd4F6	MnHJNE0zKM7:TR?=	MWq0JIQ>	NFrRU\|ZFVVOR	M3zYc4Rm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=	M1O3[lI3Ozl5MkKz
Mel290	Ml\DR4VtdCCYaXHibYxqfHliQYPzZZk>	NF7xd48xNTJizszN	MlPWOEBl	M1TDcmROW09?	NHLFfXdl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK=	MkXGNlY{QTd{MkO=
92.1	M{jrSmNmdGxiVnnhZoltcXS7IFHzd4F6	M{fWWFAuOiEQvF2=	NIfWSJA1KGR?	MYLEUXNQ	NGnJcWVl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK=	NFvKV3gzPjN7N{KyNy=>
Omm1.3	MYjD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	MnzvNE0zKM7:TR?=	MmLhOEBl	MVPEUXNQ	NGm3boll\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK=	M{L2[VI3Ozl5MkKz
Mel202	NVnJcohOS2WubDDWbYFjcWyrdImgRZN{[Xl?	MlS4NE0zKM7:TR?=	NFTXTGc1KGR?	NVvzb2xWTE2VTx?=	M{O3OIRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=	NXfJ[\|IxOjZ\|OUeyNlM>
Mel270	NEj4TFJE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	NEXDOlIxNTJizszN	NIC2eI81KGR?	NEPkV4dFVVOR	MWXk[YNz\WG\|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ?	Mo\DNlY{QTd{MkO=
Omm1	MmCyR4VtdCCYaXHibYxqfHliQYPzZZk>	NXHlS2E4OC1{IN88US=>	MXi0JIQ>	NEmwW5hFVVOR	Mnnl[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:\|ZT3k[ZBmdmSnboSgcYFvdmW{	MkLmNlY{QTd{MkO=
92.1	M1\ofGFxd3C2b4Ppd{BCe3OjeR?=	NF34b2k2ODBibl2=	MniwOFghcA>?	NXfjXlFNTE2VTx?=	MVjpcoR2[2W\|IHHwc5B1d3Orcx?=	NFeyXIIzPjN7N{KyNy=>
Omm1.3	MUfBdI9xfG:\|aYOgRZN{[Xl?	Mm\jOVAxKG6P	MYi0PEBp	Mly4SG1UVw>?	MUjpcoR2[2W\|IHHwc5B1d3Orcx?=	NV7WVmEzOjZ\|OUeyNlM>
92.1	MmjJR4VtdCCFeXPs[UBCe3OjeR?=	MXS1NFAhdk1?	M{TZZVI1NzR6L{eyJIg>	NIO2O\|lFVVOR	NUHMV29xcW6mdXPld{B1cGViY3XscEBi[2O3bYXsZZRqd25iYYSgd5VjNUdzwrC=	NHHqR5UzPjN7N{KyNy=>
Omm1.3	NXLxSYZiS2WubDDDfYNt\SCDc4PhfS=>	NXTH[\|dMPTByIH7N	MoW3NlQwPDhxN{KgbC=>	NYjzeGI3TE2VTx?=	M1XIbIlv\HWlZYOgeIhmKGOnbHygZYNkfW23bHH0bY9vKGG2IIP1Zk1IOcLi	NU\RTlBxOjZ\|OUeyNlM>
A549	NVrEbGNsTnWwY4Tpc44hSXO\|YYm=	M{LCW\|ExOC92MECvNVAxOCCwTR?=	NUXM[mp2OjRiaB?=		NE\1blJ2eHKnZ4XsZZRmeyCjbnSgZYN1cX[jdHXzJHNKWlRz	NIqwTpIzPjJzMkG5PS=>
MCF-7	NUDFOW5XTnWwY4Tpc44hSXO\|YYm=	NEDRTnMyODBxNECwM\|ExODBibl2=	M3TkeFI1KGh?		Mm\CeZBz\We3bHH0[ZMh[W6mIHHjeIl3[XSnczDTTXJVOQ>?	M{HvWlI3OjF{MUm5
HEK293	MoXISpVv[3Srb36gRZN{[Xl?	M4L1eVExOC92MECvNVAxOCCwTR?=	MXSyOEBp		MnvmeZBz\We3bHH0[ZMh[W6mIHHjeIl3[XSnczDTTXJVOQ>?	NV36TmlpOjZ{MUKxPVk>
858	NImwTYRE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	MkTDNE0yKM7:TR?=	M4TWXVUh\A>?	M3n0XWROW09?	M{nLZ4Rm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=	NHHKdHAzPjJyNkOzNy=>
DDR2L63V	M2q3eWNmdGxiVnnhZoltcXS7IFHzd4F6	MXSwMVEh\|ryP	M3XQUFUh\A>?	Mn;HSG1UVw>?	NXzOPHhR\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy	NVS4Z41iOjZ{ME[zN\|M>
BE(2)-C	NYfhN2w4S2WubDDWbYFjcWyrdImgRZN{[Xl?	M2\hVlEh\|ryP	NUTadFFuOS12IHS=		M1n4dIRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDzbYdvcW[rY3HueIx6	NXvEdYtXOjZyNke0OlQ>
IMR-32	MmP2R4VtdCCYaXHibYxqfHliQYPzZZk>	MYexJO69VQ>?	M4H6OFEuPCCm		M2SybYRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDzbYdvcW[rY3HueIx6	NVm4WlBjOjZyNke0OlQ>
JF	MXHD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	NFLkcG4yKM7:TR?=	NVnacJZPOS12IHS=		M2H1VIRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDzbYdvcW[rY3HueIx6	NXz0OoZlOjZyNke0OlQ>
BE(2)-M17	M1LHcGNmdGxiVnnhZoltcXS7IFHzd4F6	M1\ySFEh\|ryP	NX\hNFZpOS12IHS=		Mnrp[IVkemWjc3XzJINmdGxidnnhZoltcXS7IIPp[45q\mmlYX70cJk>	NH;sS2EzPjB4N{S2OC=>
SK-N-SH	MoT6R4VtdCCYaXHibYxqfHliQYPzZZk>	NUnHXpRmOSEQvF2=	NWLNeZhpOS12IHS=		M1rOR4Rm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDzbYdvcW[rY3HueIx6	M4DxW\|I3ODZ5NE[0
SK-N-DZ	MXrD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	M3\kZlEh\|ryP	Mn7PNU01KGR?		NGrIXIJl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgd4lodmmoaXPhcpRtgQ>?	MkfqNlYxPjd2NkS=
HMC-1.1	Mn;wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2K1OFUuPTByMDDuUS=>	NV[wTWx{PDhiaB?=	MkHqSG1UVw>?	M2WxfYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz	NH[wbXkzPjB3NUOwNy=>
HMC-1.2	NX\pTYYxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1LEdVUuPTByMDDuUS=>	MnfPOFghcA>?	MkHMSG1UVw>?	NUDpbmJ7cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ?	NVS4SopNOjZyNUWzNFM>
ROSA KIT WT	M3fpV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NW\4SZlLPS13MECwJI5O	NXXOWppMPDhiaB?=	NYPMR4NJTE2VTx?=	M4\QdIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz	Mn\wNlYxPTV\|MEO=
ROSA KIT D816V	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXu1MVUxODBibl2=	NGS5VWI1QCCq	Mle1SG1UVw>?	M2qzOIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz	NHvUdpkzPjB3NUOwNy=>
HMC-1.1	Mn3IRZBweHSxc3nzJGF{e2G7	MV6yNFAuPTByMDDuUS=>	NEe5cWU1QCCq	M4CyWmROW09?	NED5PWlqdmS3Y3XzJINmdGxiYYDvdJRwe2m\|IHnuJIEh\G:\|ZT3k[ZBmdmSnboSgcYFvdmW{	NXexc\|V6OjZyNUWzNFM>
HMC-1.2	MXPBdI9xfG:\|aYOgRZN{[Xl?	NIjudVMzODBvNUCwNEBvVQ>?	NFj4d4M1QCCq	NV7SRYlSTE2VTx?=	M4TKWYlv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ?	NYP3fFI3OjZyNUWzNFM>
ROSA KIT WT	MWnBdI9xfG:\|aYOgRZN{[Xl?	NGnafFQzODBvNUCwNEBvVQ>?	MnH6OFghcA>?	M1Htd2ROW09?	M4TuRYlv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ?	M2qxNFI3ODV3M{Cz
ROSA KIT D816V	M1TjVWFxd3C2b4Ppd{BCe3OjeR?=	MWeyNFAuPTByMDDuUS=>	MlvvOFghcA>?	M{XnZmROW09?	NFfCclVqdmS3Y3XzJINmdGxiYYDvdJRwe2m\|IHnuJIEh\G:\|ZT3k[ZBmdmSnboSgcYFvdmW{	NV3mNYZVOjZyNUWzNFM>
494H	NXXVeI5yT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NEDOSWc4OiCq	M{XCfGROW09?	NUC3PGdwUUN3ME2wMlEzOsLzMD6wNFQh\|ryP	NHrw[IozPTl2NEW2Oi=>
493H	MnPQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MUG3NkBp	M3;HSGROW09?	MVfJR\|UxRTBwMES3xtExNjByOTFOwG0>	NGLEUZYzPTl2NEW2Oi=>
716H	NGH3e4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M1TCPVczKGh?	NWCyTlh7TE2VTx?=	MULJR\|UxRTBwMkGyxtExNjB\|NDFOwG0>	M{DlUFI2QTR2NU[2
148I	NGT4Z2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M3rGclczKGh?	MVfEUXNQ	NE[2SYJKSzVyPUCuNlg1yrFyLkCzOUDPxE1?	MXmyOVk1PDV4Nh?=
98Sc	M3rHdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MnrqO\|IhcA>?	NVnUdZNCTE2VTx?=	M1\mZmlEPTB;MD6xNVXDuTBwMEC0JO69VQ>?	NEP3d4ozPTl2NEW2Oi=>
89R	NXvmRXE3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MYi3NkBp	M3zsU2ROW09?	Mo[4TWM2OD1yLkGyOuKyOC5yMEOg{txO	MW[yOVk1PDV4Nh?=
494L	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NYTsZ45zPzJiaB?=	M3XNdGROW09?	MVLJR\|UxRTBwM{G3xtExNjBzMjFOwG0>	NX\0Xop6OjV7NES1OlY>
493L	NVXYR\|VIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M1e2Z\|czKGh?	M3LyU2ROW09?	M4rRS2lEPTB;MD6wOVDDuTBwMEGxJO69VQ>?	NWKwSXlmOjV7NES1OlY>
148L	NVfYdm0{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MlfpO\|IhcA>?	M17M[2ROW09?	MXjJR\|UxRTBwMUS2xtExNjBzNzFOwG0>	Mnv5NlU6PDR3Nk[=
98L	M2[xfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M4\odlczKGh?	M4\VPGROW09?	M1ftTWlEPTB;MD6zNFnDuTBwMEK5JO69VQ>?	M3jaOFI2QTR2NU[2
OS17	M1jW[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MUe3NkBp	MX;EUXNQ	MlnoTWM2OD1yLkC3PeKyOC5yMEOg{txO	NWKyfFg{OjV7NES1OlY>
OS9	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NHnhdWg4OiCq	NFXpZ45FVVOR	MnfrTWM2OD1yLkSwOuKyOC5yMkig{txO	M2fY[lI2QTR2NU[2
MG63	NF\iWFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NV2zOlB6PzJiaB?=	MXnEUXNQ	M2nVN2lEPTB;MD6xNVTDuTBwMEK1JO69VQ>?	MnnwNlU6PDR3Nk[=
SAOS2	NIPMWYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NWHGcm9GPzJiaB?=	MmTWSG1UVw>?	M2\4fGlEPTB;MD6yNVfDuTBwMECzJO69VQ>?	NVrLNYZYOjV7NES1OlY>
U2OS	Mn\ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NHqyOYQ4OiCq	NITZRolFVVOR	MlT0TWM2OD1yLkG5POKyOC5yMEig{txO	MWOyOVk1PDV4Nh?=
SJSA-1	MmjUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MX63NkBp	NXX5cGk3TE2VTx?=	MXPJR\|UxRTBwMUCwxtExNjBzMDFOwG0>	NF3MdJkzPTl2NEW2Oi=>
494H	NU\IOndRSXCxcITvd4l{KEG\|c3H5	NUXHUYNxOC5{NT:wMlUwOS5yIN88US=>	MnTGNlQhcA>?	NVXOW3FbTE2VTx?=	MWnpcoNz\WG\|ZYOgcIV3\Wy\|IH;mJINt\WG4ZXSgZ4F{eGG\|ZT2zxsA>	MlziNlU6PDR3Nk[=
148I	NVThVZcySXCxcITvd4l{KEG\|c3H5	MnXpNE4zPS9yLkWvNU4xKM7:TR?=	MmK1NlQhcA>?	M3TvZ2ROW09?	NGfITIlqdmO{ZXHz[ZMhdGW4ZXzzJI9nKGOuZXH2[YQh[2G\|cHHz[U0{yqB?	M4PnW\|I2QTR2NU[2
OS17	NGP1Wm5CeG:ydH;zbZMhSXO\|YYm=	NXfPb49QOC5{NT:wMlUwOS5yIN88US=>	M1;rUVI1KGh?	NHm5PVdFVVOR	MmXTbY5kemWjc3XzJIxmfmWuczDv[kBkdGWjdnXkJINie3Cjc3WtN:Kh	M4\FOFI2QTR2NU[2
494H	NUTyTWdMSXCxcITvd4l{KEG\|c3H5	MlHyNgKBkc7:TR?=	MoXyOFghcA>?	M33tS2ROW09?	MVnpcoR2[2W\|IHPlcIwh[XCxcITvd4l{KHOrZ37p[olk[W62bIm=	M4TyPFI2QTR2NU[2
148I	NUTXNYloSXCxcITvd4l{KEG\|c3H5	Mn70NgKBkc7:TR?=	M3\u[FQ5KGh?	MXPEUXNQ	NX;wOWVDcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDzbYdvcW[rY3HueIx6	M{i2NVI2QTR2NU[2
OS17	MWjBdI9xfG:\|aYOgRZN{[Xl?	Mn7wNgKBkc7:TR?=	NGnYZ2o1QCCq	MnP2SG1UVw>?	NUCzV\|d1cW6mdXPld{Bk\WyuIHHwc5B1d3OrczDzbYdvcW[rY3HueIx6	NWP4ZotEOjV7NES1OlY>
MOLM13	MWHBdI9xfG:\|aYOgRZN{[Xl?	M17nblI2OCCwTR?=	NWDoWJkxPDhiaB?=	NHvEe\|VFVVOR	MU\pcoR2[2W\|IIPp[45q\mmlYX70cJkh[XCxcITvd4l{KGOxdILlZZRu\W62IIfpeIgheXWrenHyeIlvcWJ?	NUfvSHpIOjVyNUO4NlU>
MV4-11	MXfBdI9xfG:\|aYOgRZN{[Xl?	MVOyOVAhdk1?	NIDRe5Q1QCCq	NUi0e25nTE2VTx?=	M{DWdYlv\HWlZYOgd4lodmmoaXPhcpRtgSCjcH;weI9{cXNiY3;0doVifG2nboSge4l1cCCzdXn6ZZJ1cW6rYh?=	NUD1[IR2OjVyNUO4NlU>
MOLM13	M3y4dGZ2dmO2aX;uJGF{e2G7	NIXhcIkzPTBibl2=	NHz5fmYzPCCq	MlSwSG1UVw>?	MlnP[Y5p[W6lZYOgdZVqgmG{dHnubYIucW6mdXPl[EBud3KnIICyNUwhSkmPLDDhcoQh[2ynYY\l[EBRSVKS	M1fGOFI2ODV\|OEK1
MV4-11	NUfEUVJPTnWwY4Tpc44hSXO\|YYm=	MnfJNlUxKG6P	NWTy[WJIOjRiaB?=	NU\uZYNzTE2VTx?=	MkHz[Y5p[W6lZYOgdZVqgmG{dHnubYIucW6mdXPl[EBud3KnIICyNUwhSkmPLDDhcoQh[2ynYY\l[EBRSVKS	NWPacHFnOjVyNUO4NlU>
MOLM13	MmXoRZBweHSxc3nzJGF{e2G7	NX7yV3R4OjVyIH7N	NFfNWJc1QCCq	NFjZZmtFVVOR	M3jt[Ilv\HWlZYOgd4lodmmoaXPhcpRtgSCjcH;weI9{cXNiY3;0doVifG2nboSge4l1cCCyb37heIlvcWJ?	M{DjTlI2ODV\|OEK1
MV4-11	Mn3oRZBweHSxc3nzJGF{e2G7	NG\2[ZYzPTBibl2=	MWW0PEBp	NHPJWoNFVVOR	MlfJbY5lfWOnczDzbYdvcW[rY3HueIx6KGGyb4D0c5NqeyClb4Ty[YF1dWWwdDD3bZRpKHCxbnH0bY5q[g>?	MVOyOVA2Ozh{NR?=
Hela	M1PXZmNmdGxiVnnhZoltcXS7IFHzd4F6	NUTWPWhKOC13MECgcm0>	MXe3NkBp	MWHEUXNQ	MlnS[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:\|ZT3k[ZBmdmSnboSgcYFvdmW{	NELqcmgzPTByOUK5OS=>
HBL-1	M1PKO2NmdGxiVnnhZoltcXS7IFHzd4F6	NUPz[\|NGOC13MECgcm0>	NF3xOmU4OiCq	NYHGfI5DTE2VTx?=	M{nSV4Rm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=	NFXhZVMzPTByOUK5OS=>
HLY-1	M4m5NmNmdGxiVnnhZoltcXS7IFHzd4F6	MYWwMVUxOCCwTR?=	M1jwOlczKGh?	NWixRoJwTE2VTx?=	MV;k[YNz\WG\|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ?	M4XUbFI2ODB7Mkm1
OCI-Ly3	M3\5WWNmdGxiVnnhZoltcXS7IFHzd4F6	MmHDNE02ODBibl2=	NXPNRWZ1PzJiaB?=	NIT4d\|VFVVOR	M3r4VYRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=	NI\D[mUzPTByOUK5OS=>
OCI-Ly10	MnH2R4VtdCCYaXHibYxqfHliQYPzZZk>	NIHEVXUxNTVyMDDuUS=>	M361NVczKGh?	NEfvVWZFVVOR	NYjTVoVP\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy	MoraNlUxODl{OUW=
SU-DHL-4	M2\vfmNmdGxiVnnhZoltcXS7IFHzd4F6	NFLn[4gxNTVyMDDuUS=>	M3HDT\|czKGh?	NX23O3lxTE2VTx?=	M1WwcoRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=	MmfCNlUxODl{OUW=
SU-DHL-5	NIPtclJE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	M1Tve\|AuPTByIH7N	NXH3ZZVyPzJiaB?=	M2G1TGROW09?	NEm1SWxl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK=	M3vkPFI2ODB7Mkm1
SU-DHL-6	M4f6c2NmdGxiVnnhZoltcXS7IFHzd4F6	MmDHNE02ODBibl2=	NILvV5M4OiCq	NVOyeVZUTE2VTx?=	NV\4VYJy\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy	NHjveHozPTByOUK5OS=>
SU-DHL-10	NF3rWmpE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	MVOwMVUxOCCwTR?=	MmH5O\|IhcA>?	NWjRPYlFTE2VTx?=	MXrk[YNz\WG\|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ?	NYPiUplJOjVyMEmyPVU>
RC-K8	MXjD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	NH2yTGcxNTVyMDDuUS=>	NFKzTG84OiCq	MmDPSG1UVw>?	NVvVcWdw\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy	NFPFN5YzPTByOUK5OS=>
OCI-Ly8	M1XyfGNmdGxiVnnhZoltcXS7IFHzd4F6	NYGyWIdsOC13MECgcm0>	MlfwO\|IhcA>?	NU\sR4hWTE2VTx?=	MoLX[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:\|ZT3k[ZBmdmSnboSgcYFvdmW{	M4fodVI2ODB7Mkm1
OCL-Ly18	MYTD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	M1XOUlAuPTByIH7N	M3\PeVczKGh?	MUjEUXNQ	MnXH[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:\|ZT3k[ZBmdmSnboSgcYFvdmW{	NYrOSVdYOjVyMEmyPVU>
OCI-Ly3	Ml3pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkKwNVczNzJ3MD:1NFAhdk1?	NGT1bY4zNzdiZB?=	M3rpbGROW09?	M37Fdolv\HWlZYOgZ4VtdC2leXPs[UBienKnc4SgZZQhe3WkLVexJJdqfGhibXnubY1idCClZXzsJIRm[XSqwrC=	MWOyOVAxQTJ7NR?=
OCI-Ly8	M1HY[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mk\JNVczNzJ3MD:1NFAhdk1?	NXzM[VRMOi95IHS=	MX\EUXNQ	M1\Feolv\HWlZYOgZ4VtdC2leXPs[UBienKnc4SgZZQhe3WkLVexJJdqfGhibXnubY1idCClZXzsJIRm[XSqwrC=	NVPZb3RlOjVyMEmyPVU>
SU-DHL-4	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWWxO\|IwOjVyL{WwNEBvVQ>?	MX2yM\|ch\A>?	M3TlRmROW09?	NVzFTI5VcW6mdXPld{Bk\WyuLXP5Z4xmKGG{cnXzeEBifCC\|dXKtS\|Ehf2m2aDDtbY5qdWGuIHPlcIwh\GWjdHlCpC=>	M3\i[\|I2ODB7Mkm1
SU-DHL-10	NIm0S2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mo\4NVczNzJ3MD:1NFAhdk1?	NUnDfJhLOi95IHS=	M{PL[2ROW09?	M1fzPIlv\HWlZYOgZ4VtdC2leXPs[UBienKnc4SgZZQhe3WkLVexJJdqfGhibXnubY1idCClZXzsJIRm[XSqwrC=	NVO5fINiOjVyMEmyPVU>
OCI-Ly3	Mn7FRZBweHSxc3nzJGF{e2G7	NGnTZWYyPzJxMkWwJI5O	MV23[C=>	NWfFSWp2TE2VTx?=	NVXBW3RLcW6lcnXhd4V{KGOjc4Dhd4UuOy95IHHjeIl3cXS7wrDzbYdvcW[rY3HueIx6	NVnVfnpIOjVyMEmyPVU>
OCI-Ly8	NWS2T2ZtSXCxcITvd4l{KEG\|c3H5	NUfYVFZ[OTd{L{K1NEBvVQ>?	NIGzPYE4\A>?	NGTuVolFVVOR	MVzpcoNz\WG\|ZYOgZ4F{eGG\|ZT2zM\|ch[WO2aY\peJnDqHOrZ37p[olk[W62bIm=	M3niWFI2ODB7Mkm1
SU-DHL-4	M4DTfWFxd3C2b4Ppd{BCe3OjeR?=	NIHKS2EyPzJxMkWwJI5O	NEDVe2k4\A>?	NWLvOYVmTE2VTx?=	M3HXPIlv[3KnYYPld{Bk[XOyYYPlMVMwPyCjY4Tpeol1gcLic3nncolncWOjboTsfS=>	NYnPbXpDOjVyMEmyPVU>
SU-DHL-10	M4jqbmFxd3C2b4Ppd{BCe3OjeR?=	NHfXZlEyPzJxMkWwJI5O	MWq3[C=>	M3v3[GROW09?	NYPuZ\|NCcW6lcnXhd4V{KGOjc4Dhd4UuOy95IHHjeIl3cXS7wrDzbYdvcW[rY3HueIx6	MkKyNlUxODl{OUW=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	pDNA-PKcs / γH2AX / Ub-γH2AX / p-c-Jun S63 / Bax; PubMed: 26119999 Chem Biol The comparative effects of the active (+)-JQ1 vs. the inactive (−)-JQ1 on the cellular responsiveness to radiation and the cell fate decision. c-Myc; PubMed: 23792448 Oncogene PEL and non-PEL (Namalwa) cells treated with indicated doses of (+)-JQ1 for 48 hours were lysed and analyzed by Western blot for the expression of c-Myc. GAPDH was used as a loading control. p27; PubMed: 23792448 Oncogene Western blot analysis showing induction of p27 upon 48 hours of treatment with (+)-JQ1. GAPDH serves as a loading control.	26119999 23792448
Growth inhibition assay	Cell viability; PubMed: 23792448 Oncogene PEL cell lines (BC1, BC3, BCBL1 and JSC1) were treated with indicated doses of (-)-JQ1 or (+)-JQ1 for 5 days and cell viability measured using an MTS assay (refer to Materials and methods). Namalwa, a Burkitt's lymphoma cell line, was used as a control.	23792448
Immunofluorescence	GM130; PubMed: 29074567 Mol Biol Cell Representative images of A549cells treated with single compounds or in combination (as indicated) are shown. MHC / EdU; PubMed: 28733670 Sci Rep C2C12 cultures were switched to DM and treated with 1 µM (+)-JQ1, (−)-JQ1, DMSO or untreated (DM only). Cells were fixed at 12, 24, 48 and 72 hours after treatment and pulsed with EdU 2 hours before fixation. EdU positive nuclei were stained with Alexa Fluor 555 and cultures immunostained for MHC.	29074567 28733670

In vivo

(+)-JQ1 (50 mg/kg) inhibits tumors growth in mice with NMC 797 xenografts. (+)-JQ1 (50 mg/kg) results in effacement of NUT nuclear speckles in mice with NMC 797 xenografts, consistent with competitive binding to nuclear chromatin. (+)-JQ1 (50 mg/kg) induces strong (grade 31) keratin expression in NMC 797 xenografts. (+)-JQ1 (50 mg/kg) promotes differentiation, tumor regression and prolonged survival in mice models of NMC xenografts. ^[1] (+)-JQ1 (50 mg/kg) results in a significant prolongation in overall survival of SCID-beige mice orthotopically xenografted after intravenous injection with MM.1S-luc+ cells compared to vehicle-treated animals. ^[2] (+)-JQ1 (50 mg/kg i.p.) leads to a highly significant increase in survival of mice bearing Raji xenografts. ^[3]

Protocol

Cell Research: ^[1]	- Collapse Cell lines: MC 11060 cells Concentrations: ~500 nM Incubation Time: 48 hours Method: Cells are seeded into white, 384-well microtiter plates at 500 cells per well in a total volume of 50 μL media. The 797, TT and TE10 cells are grown in DMEM containing 1% penicillin/streptomycin and 10% FBS. The Per403 cells are grown in DMEM containing 1 % penicillin/streptomycin and 20% FBS. Patient-derived NMC 11060 cells are grown in RPMI with 10% FBS and 1% penicillin/streptomycin. (+)-JQ1 is delivered to microtiter assay plates by robotic pin transfer. Following a 48 hours incubation at 37℃, cells are lysed and wells are assessed for total ATP content using a commercial proliferation assay. Replicate measurements are analyzed with respect to dose and estimates of IC50 are calculated by logistic regression (GraphPad Prism). (Only for Reference)
Animal Research: ^[1]	- Collapse Animal Models: Mice bearing NMC 797 xenografts Formulation: 5% DMSO in 5% dextrose Dosages: 50 mg/kg Administration: intraperitoneal injection (Only for Reference)

Cell Research:

^[1]

- Collapse

Cell lines: MC 11060 cells
Concentrations: ~500 nM
Incubation Time: 48 hours
Method:
Cells are seeded into white, 384-well microtiter plates at 500 cells per well in a total volume of 50 μL media. The 797, TT and TE10 cells are grown in DMEM containing 1% penicillin/streptomycin and 10% FBS. The Per403 cells are grown in DMEM containing 1 % penicillin/streptomycin and 20% FBS. Patient-derived NMC 11060 cells are grown in RPMI with 10% FBS and 1% penicillin/streptomycin. (+)-JQ1 is delivered to microtiter assay plates by robotic pin transfer. Following a 48 hours incubation at 37℃, cells are lysed and wells are assessed for total ATP content using a commercial proliferation assay. Replicate measurements are analyzed with respect to dose and estimates of IC50 are calculated by logistic regression (GraphPad Prism).

(Only for Reference)

Animal Research:

^[1]

- Collapse

Animal Models: Mice bearing NMC 797 xenografts
Formulation: 5% DMSO in 5% dextrose
Dosages: 50 mg/kg
Administration: intraperitoneal injection
(Only for Reference)

References

[4] Li Z, et al. Nucleic Acids Res, 2013, 41(1), 277-287.

- Collapse

Solubility (25°C)

In vitro	DMSO	91 mg/mL warmed (199.12 mM)
	Ethanol	91 mg/mL (199.12 mM)
	Water	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 2% DMSO+30% PEG 300+5% Tween 80+ddH2O For best results, use promptly after mixing.	5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download (+)-JQ1 SDF

Molecular Weight	456.99
Formula	C₂₃H₂₅ClN₄O₂S
CAS No.	1268524-70-4
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
How can I reconstitute the compound for in vivo injection?
Answer:
JQ1 does not dissolve in water/PBS. The vehicle we recommend is 2% DMSO+30% PEG 300+5% Tween 80+ddH2O. The compound can be dissolved in the vehicle at 5mg/ml and you can use it for IV injection.

Epigenetic Reader Domain Signaling Pathway Map

Epigenetic Reader Domain Inhibitors with Unique Features

Pan BET Inhibitor

Bromosporine : Pan-BET inhibitor, BRD2, IC50=0.41 μM; BRD4, IC50=0.29 μM; BRD9, IC50=0.122 μM; CECR2, IC50=0.017 μM.
BET Inhibitor in Clinical Trial

RVX-208 ^New : Phase II for Dyslipidemia.
Newest BET Inhibitor

I-BET-762 : Inhibitor for BET proteins with IC50 of ~35 nM, suppresses the production of proinflammatory proteins by macrophages and blocks acute inflammation, highly selective over other bromodomain-containing proteins.
Classic BET Inhibitor

I-BET151 (GSK1210151A) : Novel selective BET inhibitor for BRD2, BRD3 and BRD4 with IC50 of 0.5 μM, 0.25 μM, and 0.79 μM, respectively.

Choose Your Country or Region

By Signaling Pathways

By product type

(+)-JQ1

Cited by 198 Publications

Purity & Quality Control

Choose Selective Epigenetic Reader Domain Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download (+)-JQ1 SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Tech Support

Frequently Asked Questions

Epigenetic Reader Domain Signaling Pathway Map

Epigenetic Reader Domain Inhibitors with Unique Features

Choose Your Country or Region

By Signaling Pathways

By product type

(+)-JQ1

Cited by 198 Publications

Purity & Quality Control

Choose Selective Epigenetic Reader Domain Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download (+)-JQ1 SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Tech Support

Frequently Asked Questions

Epigenetic Reader Domain Signaling Pathway Map

Epigenetic Reader Domain Inhibitors with Unique Features

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)